Advanced search

Germline variants and response to systemic therapy in advanced prostate cancer.

Eric Johnson, Roberto Nussenzveig, Neeraj Agarwal, Umang Swami

Journal: Pharmacogenomics 2020;21(1):75-81

PMID: 31849283

Full Text on Atypon View on PubMed

Abstract

Our current understanding of prostate cancer pharmacogenomics is growing at a rapid pace. Apart from evaluating relevant biomarkers and genomic alterations in tumor tissues, an increasing focus is being placed on decoding the impact of germline alterations on prostate cancer and its treatment. Herein we summarize various germline variants that have shown to associate with response to systemic therapy in men with advanced prostate cancer. Covered biomarkers include , , genes involved in homologous recombination and DNA mismatch repair.

Address: Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
DOI: 10.2217/pgs-2019-0125

Link outs

Free resources

Medical:

Research Materials:

Subscription / membership required

Full Text Sources:

MeSH Terms: Biomarkers, Tumor, DNA Mismatch Repair, DNA Repair, Germ Cells, Germ-Line Mutation, Homologous Recombination, Humans, Male, Multienzyme Complexes, Organic Anion Transporters, Poly(ADP-ribose) Polymerases, Progesterone Reductase, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Steroid Isomerases
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.